Wells sees potential upside after Glaukos' iDose repeat dosing label approved [Yahoo! Finance]
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
Label appears broad though with some corneal-safety limits. Overall, Wells views this as supportive of the long-term iDose annuity model. The firm has an Overweight rating on the shares with a price target of $122. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See today's best-performing stocks on TipRanks Read More on GKOS: Disclaimer & Disclosure Report an Issue Glaukos announces FDA approval of iDose TR NDA labeling supplement Glaukos price target raised to $160 from $115 at Stifel Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors Glaukos falls -8.5% Video: Wells Fargo dips as big bank earnings continue
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos (NYSE:GKOS) had its price target raised by analysts at BTIG Research from $123.00 to $131.00. They now have a "buy" rating on the stock.MarketBeat
- Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR [Yahoo! Finance]Yahoo! Finance
- Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TRBusiness Wire
- What Makes Glaukos (GKOS) a Good Investment? [Yahoo! Finance]Yahoo! Finance
- Glaukos (NYSE:GKOS) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $160.00. They now have a "buy" rating on the stock.MarketBeat
GKOS
Earnings
- 10/29/25 - Beat
GKOS
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- 1/23/26 - Form 4
- GKOS's page on the SEC website